


REMARKS

The current amendment relates to chiral amino-tetralin compounds that are muscarinic receptor antagonists. The parent application discloses "individual isomers or racemic or nonracemic mixtures of isomers (page 4, line 27) of amino tetralin derivatives. Example 3 describes the preparation of a chiral compound, {4-[(*R*)-7-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl]-propyl-amino]-piperidin-1-yl}-piperidin-4-yl-methanone (page 34, line 13 to page 36, line 17). Thus this continuation merely claims subject matter which the applicant has previously described and this amendment does not introduce new matter.

The preliminary amendment places the application in condition for examination and prompt review of the merits of the case is respectfully requested. A copy of form 1449 submitted with the parent case is included; copies of the references can be found in the parent case. While the fees noted on the fee transmittal are believed to be correct, authorization is hereby give to debit any deficiency from, or credit any surplus to, our deposit account 18-1700. The Examiner is invited to contact the undersigned if any additional information is required.

Respectfully submitted,



Brian L. Buckwalter
Registration No. 46,585
Agent for Applicants

June 26, 2003

Roche Palo Alto, LLC
Patent Law Dept., M/S A2-250
3431 Hillview Ave, Palo Alto, CA 94304
Direct Telephone 650-855-6995
Fax: 650-855-5322